Brief: Gracell Biotechnologies Doses First Patients In First-In-Human Clinical Trial Evaluating Gc012f In B-Cell Non-Hodgkin's Lymphoma
17/02/2022 13:33
Feb 17 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES DOSES FIRST PATIENTS IN
FIRST-IN-HUMAN
CLINICAL TRIAL EVALUATING GC012F, ITS DUAL-TARGETING FASTCAR-T
THERAPY, IN B-CELL NON-HODGKIN'S LYMPHOMA
Source text for Eikon: ID:nPn3TZLFca
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27